EcoDrugPlus

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSMMDG00005005013
Gene Symbol: MAPK1
1 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSMMDG00005011250
Gene Symbol: LOC115363907
3 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSMMDG00005004116
Gene Symbol: MAPK10
1 Cross references
88 Possible Orthologues:

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSMMDG00005024064
Gene Symbol: LOC115355376
3 Cross references
199 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSMMDG00005020368
Gene Symbol: MAPK14
1 Cross references
206 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a

Ensembl ID : ENSMMDG00005003522
Gene Symbol: LOC115359126
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSMMDG00005010793
Gene Symbol: LOC115377689
3 Cross references
225 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSMMDG00005012734
Gene Symbol: LOC115372312
3 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSMMDG00005019460
Gene Symbol: MAPK9
3 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSMMDG00005010104
Gene Symbol: MAP2K1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSMMDG00005006720
Gene Symbol: MAP3K10
1 Cross references
182 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSMMDG00005010901
Gene Symbol: MAP3K11
1 Cross references
182 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).